Discovering and validating unknown phospho-sites from p38 and HuR protein kinases in vitro by Phosphoproteomic and Bioinformatic tools

Journal of Clinical Bioinformatics

Volumn 1, Issue 1, 2011, Pages

  López, Elena ^a,d   López, Isabel ^b   Sequí, Julia ^c   Ferreira, Antonio ^c  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL QUIRÓN   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871925671     PISSN: None     EISSN: 20439113     Source Type: Journal    
DOI: 10.1186/2043-9113-1-16     Document Type: Article

References (61)

1. Han J, Sun P. The pathways to tumor suppression via route p38. Trends Biochem Sci 2007, 32(8):364-371. 2007, 10.1016/j.tibs.2007.06.007, 17624785.
2. Lluis F, Perdiguero E, Nebreda AR, Munoz-Canoves P. Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol 2006, 16(1):36-44. 2006, 10.1016/j.tcb.2005.11.002, 16325404.
3. Zarubin T, Han J. Activation and signalling of the p38 MAP kinase pathway. Cell Res 2005, 15(1):11-18. 2005, 10.1038/sj.cr.7290257, 15686620.
4. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007, 1773(8):1358-1375. 2007, 10.1016/j.bbamcr.2007.03.010, 17481747.
5. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, Nebreda AR. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007, 11(2):191-205. 2007, 10.1016/j.ccr.2006.12.013, 17292829.
6. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010, 429(3):403-417. 10.1042/BJ20100323, 20626350.
7. Kim HH, Gorospe M. Phosphorylated HuR shuttles in cycles. Cell Cycle 2008, 7(20):3124-3126. 2008, 10.4161/cc.7.20.6884, 2577782, 18927508.
8. Abdelmohsen K, Pullmann R, Lal A, Kim HH, Galban S, Yang X, Blethrow JD, Walker M, Shubert J, Gillespie DA, Furneaux H, Gorospe M. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell 2007, 25(4):543-557. 2007b, 10.1016/j.molcel.2007.01.011, 1986740, 17317627.
9. Doller A, Huwiler A, Muller R, Radeke HH, Pfeilschifter J, Eberhardt W. Protein kinase C alpha-dependent phosphorylation of the mRNA-stabilizing factor HuR: implications for posttranscriptional regulation of cyclooxygenase-2. Mol Biol Cell 2007, 18(6):2137-2148. 2007, 10.1091/mbc.E06-09-0850, 1877114, 17392515.
10. Jin SH, Kim TI, Yang KM, Kim WH. Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR. Eur J Pharmacol 2007, 558(1-3):14-20. 2007, 10.1016/j.ejphar.2006.11.060, 17208222.
11. Kim HH, Yang X, Kuwano Y, Gorospe M. Modification at HuR(S242) alters HuR localization and proliferative influence. Cell Cycle 2008, 7(21). 2008b.
12. Kim HH, Abdelmohsen K, Lal A, Pullmann R, Yang X, Galban S, Srikantan S, Martindale JL, Blethrow J, Shokat KM, Gorospe M. Nuclear HuR accumulation through phosphorylation by Cdk1. Genes Dev 2008, 22(13):1804-1815. 2008a, 10.1101/gad.1645808, 2492667, 18593881.
13. Wang W, Furneaux H, Cheng H, Caldwell MC, Hutter D, Liu Y, Holbrook N, Gorospe M. HuR regulates p21 mRNA stabilization by UV light. Mol Cell Biol 2000, 20(3):760-769. 2000, 10.1128/MCB.20.3.760-769.2000, 85192, 10629032.
14. Lafarga V, Cuadrado A, Lopez de Silanes I, Bengoechea R, Fernandez-Capetillo O, Nebreda AR. p38 Mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint. Mol Cell Biol 2009, 29(16):4341-4351. 2009, 10.1128/MCB.00210-09, 2725730, 19528229.
15. Kim HH, Abdelmohsen K, Gorospe M. Regulation of HuR by DNA Damage Response Kinases. J Nucleic Acids 2010, 25:2010.
16. Lopez de Silanes I, Fan J, Yang X, Zonderman AB, Potapova O, Pizer ES, Gorospe M. Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene 2003, 22(46):7146-7154. 2003, 10.1038/sj.onc.1206862, 14562043.
17. Abdelmohsen K, Lal A, Kim HH, Gorospe M. Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle 2007, 6(11):1288-1292. 2007a, 10.4161/cc.6.11.4299, 17534146.
18. Doller A, Pfeilschifter J, Eberhardt W. Signalling pathways regulating nucleo-cytoplasmic shuttling of the mRNA-binding protein HuR. Cell Signal 2008, 20(12):2165-2173. 2008, 10.1016/j.cellsig.2008.05.007, 18585896.
19. Fernau NS, Fugmann D, Leyendecker M, Reimann K, Grether-Beck S, Galban S, Ale-Agha N, Krutmann J, Klotz LO. Role of HuR and p38MAPK in ultraviolet B-induced post-transcriptional regulation of COX-2 expression in the human keratinocyte cell line HaCaT. J Biol Chem 2010, 285(6):3896-3904. 2010, 10.1074/jbc.M109.081430, 2823532, 19917608.
20. Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ. Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 2003, 278(39):37637-37647. 2003, 10.1074/jbc.M301481200, 12826679.
21. Farooq F, Balabanian S, Liu X, Holcik M, MacKenzie A. p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR. Hum Mol Genet 2009, 18(21):4035-4045. 2009, 10.1093/hmg/ddp352, 19648294.
22. Shi Y, Gaestel M. In the cellular garden of forking paths: how p38 MAPKs signal for downstream assistance. Biol Chem 2002, 383(10):1519-1536. 20002, 10.1515/BC.2002.173, 12452429.
23. Thingholm TE, Larsen MR, Ingrell CR, Kassem M, Jensen ON. TiO(2)-based phosphoproteomic analysis of the plasma membrane and the effects of phosphatase inhibitor treatment. J Proteome Res 2008, 7(8):3304-13. 2008, 10.1021/pr800099y, 18578522.
24. Thingholm TE, Jensen ON, Larsen MR. Enrichment and separation of mono- and multiply phosphorylated peptides using sequential elution from IMAC prior to mass spectrometric analysis. Methods Mol Biol 2009, 527:67-78. (2009) Review, 10.1007/978-1-60327-834-8_6, 19241006.
25. Ashman K, Lopez-Villar E. Phosphoproteomics and cancer research. Clin Transl Oncol 2009, 11(6):356-62. (2009) Review, 10.1007/s12094-009-0369-z, 19531450.
26. Palmisano G, Thingholm TE. Strategies for quantitation of phosphoproteomic data. Expert Rev Proteomics 2010, 7(3):439-56. (2010) Review, 10.1586/epr.10.19, 20536313.
27. López E, Matthiesen R, López I, Ashman K, Mendieta J, Wesselink JJ, Gómez-Puertas P, Ferreira A. Functional phosphoproteomics tools for current immunological disorders research. JOURNAL OF INTEGRATED OMICS 2011, 1(1):1-16., HTTP://WWW.JIOMICS.COM
28. Miller ML, Blom N. Kinase-specific prediction of protein phosphorylation sites. Methods Mol Biol 2009, 527:299-310. 2009, 10.1007/978-1-60327-834-8_22, 19241022.
29. Zhao X, León IR, Bak S, Mogensen M, Wrzesinski K, Højlund K, Jensen ON. Phosphoproteome analysis of functional mitochondria isolated from resting human muscle reveals extensive phosphorylation of inner membrane protein complexes and enzymes. Mol Cell Proteomics 2011, 10(1):M110.000299. 2011, 10.1074/mcp.M110.000299, 20833797.
30. Larsen MR, Thingholm TE, Jensen ON, Roepstorff P, Jørgensen TJ. Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol Cell Proteomics 2005, 4(7):873-86. 2005, 10.1074/mcp.T500007-MCP200, 15858219.
31. Thingholm TE, Jørgensen TJ, Jensen ON, Larsen MR. Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat Protoc 2006, 1(4):1929-35. 2006, 10.1038/nprot.2006.185, 17487178.
32. Nühse TS, Stensballe A, Jensen ON, Peck SC. Large-scale analysis of in vitro phosphorylated membrane proteins by immobilized metal ion affinity chromatography and mass spectrometry. Mol Cell Proteomics 2003, 2(11):1234-43. 10.1074/mcp.T300006-MCP200, 14506206.
33. Lee J, Xu Y, Chen Y, Sprung R, Kim SC, Xie S, Zhao Y. Mitochondrial phosphoproteome revealed by an improved IMAC method and MS/MS/MS. Mol Cell Proteomics 2007, 6(4):669-76. 2007, 10.1074/mcp.M600218-MCP200, 2902983, 17208939.
34. Thingholm TE, Jensen ON, Robinson PJ, Larsen MR. SIMAC (sequential elution from IMAC), a phosphoproteomics strategy for the rapid separation of monophosphorylated from multiply phosphorylated peptides. Mol Cell Proteomics 2008, 7(4):661-71. 2008.
35. Jensen SS, Larsen MR. Evaluation of the impact of some experimental procedures on different phosphopeptide enrichment techniques. Rapid Commun Mass Spectrom 2007, 21(22):3635-45. 2007, 10.1002/rcm.3254, 17939157.
36. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol 2003, 21(3):255-61. 2003, 10.1038/nbt0303-255, 12610572.
37. Gruhler A, Olsen JV, Mohammed S, Mortensen P, Faergeman NJ, Mann M, Jensen ON. Quantitative phosphoproteomics applied to the yeast pheromone signalling pathway. Mol Cell Proteomics 2005, 4(3):310-27. 2005, 10.1074/mcp.M400219-MCP200, 15665377.
38. Thingholm TE, Jensen ON, Larsen MR. Analytical strategies for phosphoproteomics. Proteomics 2009, 9(6):1451-68. (2009) Review, 10.1002/pmic.200800454, 19235172.
39. Patel SB, Cameron PM, O'Keefe SJ, Frantz-Wattley B, Thompson J, O'Neill EA, Tennis T, Liu L, Becker JW, Scapin G. The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha. Acta Crystallogr D Biol Crystallogr 2009, 65(Pt 8):777-85. 2009.
40. Benoit RM, Meisner N-C, Kallen J, Graff P, Hemmig R, Cèbe1 R, Ostermeier C, Widmer H, Auer M. The X-ray Crystal Structure of the First RNA Recognition Motif and Site-Directed Mutagenesis Suggest a Possible HuR Redox Sensing Mechanism. J Mol Biol 2010, 397:1231-1244. 2010, 10.1016/j.jmb.2010.02.043, 20219472.
41. Guex N, Diemand A, Peitsch MC. Protein modelling for all. Trends Biochem Sci 1999, 24:364-367. 1999, 10.1016/S0968-0004(99)01427-9, 10470037.
42. Peitsch MC. ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling. Biochem Soc Trans 1996, 24:274-279. 1996.
43. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res 2003, 31:3381-3385. 2003, 10.1093/nar/gkg520, 168927, 12824332.
44. Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Onufriev A, Simmerling C, Wang B, Woods RJ. The Amber biomolecular simulation programs. J Comput Chem 2005, 26:1668-1688. 2005, 10.1002/jcc.20290, 1989667, 16200636.
45. Mendieta J, Fuertes MA, Kunchitapatham R, Santa-María I, Moreno FJ, Alonso C, Gago F, Muñoz V, Avila J, Hernández F. Phosphorylation Modulates the Alpha Helical Structure and Polymerization of a Peptide from the Third Tau Microtubule-Binding Repeat. Biochim Biophys Acta 2005, 1721:16-26. 2005.
46. Thingholm TE, Larsen MR, Ingrell CR, Kassem M, Jensen ON. TiO(2)-based phosphoproteomic analysis of the plasma membrane and the effects of phosphatase inhibitor treatment. J Proteome Res 2008, 7(8):3304-13. 2008, 10.1021/pr800099y, 18578522.
47. Schroeder MJ, Shabanowitz J, Schwartz JC, Hunt DF, Coon JJ. A neutral loss activationmethod for improved phosphopeptide sequence analysis by quadrupole ion trap mass spectrometry. Anal Chem 2004, 76:3590-3598. 2004, 10.1021/ac0497104, 15228329.
48. Jiang X, Ye M, Han G, Dong X, Zou H. Classification filtering strategy to improve the coverage and sensitivity of phosphoproteome analysis. Anal Chem 2010, 82(14):6168-75. (2010) 15, 10.1021/ac100975t, 20568719.
49. Villén J, Beausoleil SA, Gygi SP. Evaluation of the utility of neutral-loss-dependent MS3 strategies in large-scale phosphorylation analysis. Proteomics 2008, 8(21):4444-52. 2008, 10.1002/pmic.200800283, 2745099, 18972524.
50. Steen H, Küster B, Mann M. Quadrupole time-of-flight versus triple-quadrupole mass spectrometry for the determination of phosphopeptides by precursor ion scanning. J Mass Spectrom 2001, 36(7):782-90. 10.1002/jms.174, 11473401.
51. Steen H, Mann M. A new derivatization strategy for the analysis of phosphopeptides by precursor ion scanning in positive ion mode. J Am Soc Mass Spectrom 2002, 13(8):996-1003. 10.1016/S1044-0305(02)00415-4, 12216740.
52. Navajas R, Paradela A, Albar JP. Immobilized metal affinity chromatography/reversed-phase enrichment of phosphopeptides and analysis by CID/ETD tandem mass spectrometry. Methods Mol Biol 2011, 681:337-48. 2011, 10.1007/978-1-60761-913-0_18, 20978974.
53. Kleinnijenhuis AJ, Kjeldsen F, Kallipolitis B, Haselmann KF, Jensen ON. Analysis of histidine phosphorylation using tandem MS and ion-electron reactions. Anal Chem 2007, 79(19):7450-6. 1, 10.1021/ac0707838, 17822303.
54. Stensballe A, Andersen S, Jensen ON. Characterization of phosphoproteins from electrophoretic gels by nanoscale Fe(III) affinity chromatography with off-line mass spectrometry analysis. Proteomics 2001, 1(2):207-22. 10.1002/1615-9861(200102)1:2<207::AID-PROT207>3.0.CO;2-3, 11680868.
55. Schroeder MJ, Webb DJ, Shabanowitz J, Horwitz AF, Hunt DF. Methods for the detection of paxillin post-translational modifications and interacting proteins by mass spectrometry. J Proteome Res 2005, 4(5):1832-41. 10.1021/pr0502020, 16212439.
56. Syka JE, Coon JJ, Schroeder MJ, Shabanowitz J, Hunt DF. Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad Sci USA 2004, 101(26):9528-33. 29, 10.1073/pnas.0402700101, 470779, 15210983.
57. Thingholm TE, Jensen ON, Larsen MR. Enrichment and separation of mono- and multiply phosphorylated peptides using sequential elution from IMAC prior to mass spectrometric analysis. Methods Mol Biol 2009, 527:67-78. 2009, 10.1007/978-1-60327-834-8_6, 19241006.
58. Meisner NC, Hintersteiner M, Mueller K, Bauer R, Seifert JM, Naegeli HU, Ottl J, Oberer L, Guenat C, Moss S, Harrer N, Woisetschlaeger M, Buehler C, Uhl V, Auer M. Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR. Nat Chem Biol 2007, 3:508-515. 10.1038/nchembio.2007.14, 17632515.
59. Besnard A, Galan-Rodriguez B, Vanhoutte P, Caboche J. Elk-1 a transcription factor with multiple facets in the brain. Front Neurosci 2011, 5:35. 16, 3060702, 21441990.
60. López E, López I, Ferreira A, Sequí J. Clinical and Technical Phosphoproteomic Research. Proteome Sci 2011, 9(1):27. 2, 10.1186/1477-5956-9-27, 3127965, 21635771.
61. Kim J-E, Tannenbaum SR, White FM. Global phosphoproteome of HT-29 human colon adenocarcinoma cells. J Proteome Res 2007, 4:1339-1346.